<code id='BFB9F8C273'></code><style id='BFB9F8C273'></style>
    • <acronym id='BFB9F8C273'></acronym>
      <center id='BFB9F8C273'><center id='BFB9F8C273'><tfoot id='BFB9F8C273'></tfoot></center><abbr id='BFB9F8C273'><dir id='BFB9F8C273'><tfoot id='BFB9F8C273'></tfoot><noframes id='BFB9F8C273'>

    • <optgroup id='BFB9F8C273'><strike id='BFB9F8C273'><sup id='BFB9F8C273'></sup></strike><code id='BFB9F8C273'></code></optgroup>
        1. <b id='BFB9F8C273'><label id='BFB9F8C273'><select id='BFB9F8C273'><dt id='BFB9F8C273'><span id='BFB9F8C273'></span></dt></select></label></b><u id='BFB9F8C273'></u>
          <i id='BFB9F8C273'><strike id='BFB9F8C273'><tt id='BFB9F8C273'><pre id='BFB9F8C273'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:explore    Page View:3283
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In